Shady Henien, MD
Interventional Cardiology · Springfield, ILNPI 1760820930
Payments from drug & device makers
Across 282 payments — averaging $373.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$45K
- Medtronic$24K
- BD$23K
- Penumbra, Inc.$5K
- W. L. Gore & Associates, Inc.$2K
- Edwards Lifesciences$1K
- plus $6K from 25 others
What the payments were for
- Consulting fees$1,4991%
- Speaking & faculty fees$1000%
- Grants$88,50084%
- Travel & lodging$5,3395%
- Food & beverage$9,7099%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 26 | $45,000 |
| Medtronic(2 entities) | 43 | $23,727 |
| BD | 15 | $23,219 |
| Penumbra, Inc. | 18 | $4,526 |
| W. L. Gore & Associates, Inc. | 18 | $1,649 |
| Edwards Lifesciences | 18 | $1,458 |
| Abbott | 14 | $952 |
| Inari Medical, Inc. | 5 | $877 |
| Boston Scientific | 15 | $572 |
| Abiomed | 4 | $407 |
| Pfizer | 17 | $356 |
| GE HealthCare | 1 | $340 |
| Cardiovascular Systems Inc. | 3 | $306 |
| Novartis | 22 | $292 |
| E.r. Squibb & Sons, L.L.C. | 6 | $221 |
| Merck | 11 | $203 |
| Amgen | 11 | $163 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $162 |
| Shockwave Medical, Inc | 3 | $136 |
| Johnson & Johnson | 7 | $119 |
| United Therapeutics Corporation | 1 | $100 |
| Kestra Medical Technology Services, Inc. | 4 | $84 |
| Philips North America LLC | 2 | $84 |
| ZOLL Circulation Inc | 1 | $68 |
| AstraZeneca | 5 | $67 |
| Cardiva Medical, Inc. | 1 | $43 |
| Impulse Dynamics (USA) Inc. | 1 | $29 |
| Cvrx, Inc. | 1 | $23 |
| Stryker | 1 | $22 |
| Bayer | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$4,272
- COREVALVE EVOLUT R$1,042
- GORE CARDIOFORM Septal Occluder$1,002
- CT THROMBECTOMY SYSTEM KIT$754
- FLOWTRIEVER CATHETER, S$754
- EXPORT AP$440
- Impella$379
- MitraClip$271
- Diamondback Coronary$159
- NAVITOR$155
- WATCHMAN FLX$144
- Diamondback Peripheral$130
- MitraClip System$129
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$128
- CAMZYOS$122
- PASCAL$113
- WATCHMAN Access System$108
- HawkOne$100
How this compares
$105,247 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 467 | $390,971 |
| EntrestoSacubitril/Valsartan | 391 | $322,325 |
| XareltoRivaroxaban | 107 | $98,757 |
| Repatha SureclickEvolocumab | 52 | $30,855 |
| BrilintaTicagrelor | 36 | $15,746 |
| FarxigaDapagliflozin Propanediol | 18 | $10,639 |
| Atorvastatin Calcium | 410 | $3,948 |
| Metoprolol Succinate | 269 | $2,828 |
| Carvedilol | 420 | $2,379 |
| ClopidogrelClopidogrel Bisulfate | 203 | $2,037 |
| Metoprolol Tartrate | 359 | $1,704 |
| Nebivolol Hcl | 30 | $1,640 |
| Amlodipine Besylate | 246 | $1,436 |
| Lisinopril | 239 | $1,376 |
| Losartan Potassium | 154 | $1,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $356 | $390,971467 claims |
| NovartisEntresto | $292 | $322,325391 claims |
| Johnson & JohnsonXarelto | $119 | $98,757107 claims |
| AstraZenecaBrilinta, Farxiga | $67 | $26,38654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Springfield
- Krishna Rocha SinghSpringfield$1.7M
- Sunil AgarwalSpringfield$609K
- Avinash MurthySpringfield$553K
- Donald YakelSpringfield$503K
- John GillSpringfield$372K
- Tony de MartiniSpringfield$208K
- Salem BadrSpringfield$94K
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Mark RicciardiEvanston$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.